Bradley Pharmaceuticals Launches Peranex(TM) HC Cream
15 Juin 2007 - 2:45PM
PR Newswire (US)
FAIRFIELD, N.J., June 15 /PRNewswire-FirstCall/ -- Bradley
Pharmaceuticals, Inc. (NYSE:BDY) today announced the launch of
Peranex(TM) HC Cream (Hydrocortisone Acetate 2% -- Lidocaine HCl
2%) by the Company's Kenwood Therapeutics division. Peranex(TM) HC
Cream is the first product in a new line of anorectal treatments
used for the anti-inflammatory and anesthetic relief of itching,
pain, soreness and discomfort due to hemorrhoids, anal fissures,
pruritus ani and similar conditions of the anal area. Peranex(TM)
HC Cream offers patients a complete way to treat hemorrhoids. Each
Peranex(TM) HC prescription contains 12 full days of therapy with
24 single-use tubes, pre-application wipes, 24 flushable cleansing
wipes, and patient information about hemorrhoids. "We are very
enthusiastic about the introduction of the new Peranex(TM) HC
brand," commented Daniel Glassman, President and CEO of Bradley
Pharmaceuticals. "Part of our business strategy is to offer new
products and line extensions that add value to both patients and
physicians. This brand alternative offers proven efficacy, more
therapy and additional components that will help make dealing with
these uncomfortable conditions easier. We expect to receive a
positive reception from both physicians and their patients."
Peranex(TM) HC Cream will be promoted to gastroenterologists and
OB/GYN physicians and is currently available from wholesalers.
Important Product Safety Information About Peranex(TM) HC Cream:
Peranex(TM) HC Cream is contraindicated for tuberculous or fungal
lesions, skin vaccinia, varicella or acute herpes simplex.
Peranex(TM) HC Cream should be used with caution by patients with
impaired liver function, significant liver disease, the elderly,
very ill, and patients taking Class I anti- arrhythmic drugs.
Transient stinging or burning from open areas of skin, or transient
lightening or redness of the skin may occur during or immediately
after use. For external use only. For additional important
information about Peranex(TM) HC Cream, please request full
prescribing information by contacting Bradley Pharmaceuticals.
Please visit the Bradley Pharmaceuticals web site at:
http://www.bradpharm.com/. About Bradley Pharmaceuticals, Inc.
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty
pharmaceutical company and markets to niche physician specialties
in the U.S. and international markets. Bradley's success is based
upon its core strengths in marketing and sales, which enable the
company to Commercialize brands that fill unmet patient and
physician needs; Develop new products through life cycle
management; and In-License phase II and phase III drugs with
long-term intellectual property protection that upon approval
leverage Bradley's marketing and sales expertise to increase
shareholder value. Bradley Pharmaceuticals is comprised of Doak
Dermatologics, specializing in therapies for dermatology and
podiatry; Kenwood Therapeutics, providing gastroenterology, OB/GYN,
respiratory and other internal medicine brands; and A. Aarons,
which markets authorized generic versions of Doak and Kenwood
therapies. Safe Harbor for Forward-Looking Statements: This release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements that address activities, events or
developments that Bradley expects, believes or anticipates will or
may occur in the future, such as Bradley's plans to in-license,
develop and launch new and enhanced products with long-term
intellectual property protection or other significant barriers to
market entry, sales and earnings estimates, other predictions of
financial performance, timing of payments on indebtedness, launches
by Bradley of new products, market acceptance of Bradley's
products, and the achievement of initiatives to enhance corporate
governance and long-term shareholder value. Forward-looking
statements are based on Bradley's experience and perception of
current conditions, trends, expected future developments and other
factors it believes are appropriate under the circumstances and are
subject to numerous risks and uncertainties, many of which are
beyond Bradley's control. These risks and uncertainties include
Bradley's ability to: launch VEREGEN(TM) at the end of 2007;
predict the safety and efficacy of these products in a commercial
setting; estimate sales; maintain adequate inventory levels;
implement the returns and inventory optimization plan timely, if at
all; reduce product returns; comply with the restrictive covenants
under its credit facility; refinance its credit facility; access
the capital markets on attractive terms or at all; favorably
resolve the pending SEC informal inquiry; maintain or increase
sales of its products; or effectively react to other risks and
uncertainties described from time to time in Bradley's SEC filings,
such as fluctuation of quarterly financial results, estimation of
product returns, chargebacks, rebates and allowances, concentration
of customers, reliance on third party manufacturers and suppliers,
litigation or other proceedings (including the pending class action
and shareholder derivative lawsuits), government regulation and
stock price volatility. Further, Bradley cannot accurately predict
the impact on its business of the approval, introduction, or
expansion by competitors of generic or therapeutically equivalent
or comparable versions of Bradley's products or of any other
competing products. In addition, actual results may differ
materially from those projected. Bradley undertakes no obligation
to publicly update any forward-looking statement, whether as a
result of new information, future events or otherwise. DATASOURCE:
Bradley Pharmaceuticals, Inc. CONTACT: Cecelia C. Heer,
Investor-Public Relations of Bradley Pharmaceuticals, Inc.,
+1-973-882-1505, ext. 252, Web site: http://www.bradpharm.com/
Copyright
Bradley (NYSE:BDY)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Bradley (NYSE:BDY)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024